Amarin Corp Plc (AMRN)

[HDGabor]

i- 305575

Based on this, anybody should think Hikma's generics is anything but B at that moment. It may become B in the future

To avoid any doubt: I do not say that based on this anybody should think Hikma's generics is "B" ... but

And again, when Hikma said "generic equivalent", it was PR of ANDA approval which normally confirms "therapeutically equivalent", correct? Therefore, it can not be "B" codes.

Normally, but is not always. It CAN be "B" upon approval, is not "A" the one and only possibility.

All I say: "the generic equivalent to Vascepa" does not equal with "A" code since - at least theoretically - it could be "B" code. It is very rare but some generics got B code upon approval, as a first code. (e.g.: "The code B* is assigned to products previously assigned an A or B code")

Best,
G